A new standard combination for recurrent ovarian cancer?

被引：9

作者：

Bast, Robert C., Jr. ^{[1
]}

Markman, Maurie ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Unit 1439, Houston, TX 77030 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2010年 / 7卷 / 10期

关键词：

TRIAL; ADRIAMYCIN;

D O I：

10.1038/nrclinonc.2010.152

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer that recurs more than 6 months following primary chemotherapy can respond to many different drugs, but retreatment with a combination of carboplatin and paclitaxel has become a standard of care. A combination of pegylated liposomal doxorubicin and carboplatin may provide a slightly, but significantly, greater therapeutic index than carboplatin and paclitaxel.

引用

页码：559 / 560

页数：2

共 10 条

[1] Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR public workshop [J].

Bast, Robert C. ;

Thigpen, J. Tate ;

Arbuck, Susan G. ;

Basen-Engquist, Karen ;

Burke, Laurie B. ;

Freedman, Ralph ;

Horning, Sandra J. ;

Ozols, Robert ;

Rustin, Gordon J. ;

Spriggs, David ;

Wenzel, Lari B. ;

Pazdur, Richard .

GYNECOLOGIC ONCOLOGY, 2007, 107 (02) :173-176

[2] Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough? [J].

Cannistra, Stephen A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3101-3103

[3]

EHRKE MJ, 1983, INT J IMMUNOPHARMACO, V5, P43

[4] Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial [J].

Markman, Maurie ;

Moon, James ;

Wilczynski, Sharon ;

Lopez, Ana Maria ;

Rowland, Kendrith M., Jr. ;

Michelin, David P. ;

Lanzotti, Victor J. ;

Anderson, Garnet L. ;

Alberts, David S. .

GYNECOLOGIC ONCOLOGY, 2010, 116 (03) :323-325

[5] Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer [J].

Monk, Bradley J. ;

Herzog, Thomas J. ;

Kaye, Stanley B. ;

Krasner, Carolyn N. ;

Vermorken, Jan B. ;

Muggia, Franco M. ;

Pujade-Lauraine, Eric ;

Lisyanskaya, Alla S. ;

Makhson, Anatoly N. ;

Rolski, Janusz ;

Gorbounova, Vera A. ;

Ghatage, Prafull ;

Bidzinski, Mariusz ;

Shen, Keng ;

Ngan, Hextan Yuen-Sheung ;

Vergote, Ignace B. ;

Nam, Joo-Hyun ;

Park, Youn Choi ;

Lebedinsky, Claudia A. ;

Poveda, Andres M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3107-3114

[6]

Parmar MKB, 2003, LANCET, V361, P2099

[7] Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG [J].

Pfisterer, Jacobus ;

Plante, Marie ;

Vergote, Ignace ;

du Bois, Andreas ;

Hirte, Hal ;

Lacave, Angel J. ;

Wagner, Uwe ;

Staehle, Anne ;

Stuart, Gavin ;

Kimmig, Rainer ;

Olbricht, Sigrid ;

Le, Tien ;

Emerich, Janusz ;

Kuhn, Walther ;

Bentley, James ;

Jackisch, Christian ;

Lueck, Hans-Joachim ;

Rochon, Justine ;

Zimmermann, Annamaria Hayden ;

Eisenhauer, Elizabeth .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4699-4707

[8] Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse [J].

Pujade-Lauraine, Eric ;

Wagner, Uwe ;

Aavall-Lundqvist, Elisabeth ;

Gebski, Val ;

Heywood, Mark ;

Vasey, Paul A. ;

Volgger, Birgit ;

Vergote, Ignace ;

Pignata, Sandro ;

Ferrero, Annamaria ;

Sehouli, Jalid ;

Lortholary, Alain ;

Kristensen, Gunnar ;

Jackisch, Christian ;

Joly, Florence ;

Brown, Chris ;

Le Fur, Nathalie ;

du Bois, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3323-3329

[9] Hypersensitivity reactions to antineoplastic agents: an overview [J].

Syrigou, Ekaterini ;

Makrilia, Nektaria ;

Koti, Ioanna ;

Saif, Muhammad W. ;

Syrigos, Kostas N. .

ANTI-CANCER DRUGS, 2009, 20 (01) :1-6

[10]

VECCHI A, 1976, CANCER RES, V36, P1222

← 1 →